ワクチン販売市場レポート：2026-2036年
Vaccine Sales Market Report 2026-2036
説明
Visiongainは新たなレポートを発表しました。 ワクチン販売市場レポート 2026-2036年 、世界のワクチン販売市場について、市場規模、成長要因、競合状況、および適応症、種類、投与経路、年齢層... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページはAI翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
|
サマリー
説明
Visiongainは新たなレポートを発表しました。ワクチン販売市場レポート 2026-2036年、世界のワクチン販売市場について、市場規模、成長要因、競合状況、および適応症、種類、投与経路、年齢層、流通チャネルごとの売上予測を含む包括的な分析を提供しています。
世界のワクチン販売市場は、2026年に764億米ドルと評価されており、予測期間中に年平均成長率（CAGR）6.3％で拡大し、2036年には1,414億米ドルに達すると予測されている。
この成長は、感染症の有病率の上昇、低・中所得国における政府資金による予防接種プログラムの拡大、およびmRNA、ウイルスベクター、無針投与技術などの次世代ワクチンプラットフォームへの投資の加速によって牽引されています。
市場拡大を牽引する技術革新
mRNA、ウイルスベクター、DNAなどのプラットフォーム型ワクチン技術は、ワクチンのパイプラインを拡大させ、複数の疾患領域にわたる製品開発を支えています。 mRNA-4157（ModernaおよびMerck）などの候補ワクチンは、がん領域におけるmRNA技術の応用が拡大していることを示しており、一方、HIV、ニパウイルス、パンデミックインフルエンザに関する進行中の研究は、ワクチン開発の分野が引き続き多様化していることを反映している。
製剤や投与方法における革新も、ワクチンの普及を後押ししています。鼻腔内投与型や経口型のワクチンは、投与を簡素化し、特に小児患者における受容性を高めています。また、溶解性マイクロアレイパッチをはじめとする新たな無針技術が開発されており、これらは物流上の複雑さを軽減し、コールドチェーンへの依存を最小限に抑え、資源の乏しい環境における自己投与を可能にするものです。
2025年12月、 CEPIは、モデルナ社のmRNAベースのH5パンデミックインフルエンザワクチン候補（mRNA-1018）の第3相臨床試験を支援するため、最大5,430万米ドルを拠出することを決定した。これにより、初のmRNAインフルエンザワクチンが重要な開発段階へと進み、次世代ワクチンプラットフォームの商業化に向けたパイプラインが強化された。
貿易、政策、およびサプライチェーンの動向
-
ワクチンの販売市場は、米国の貿易関税政策、公共調達枠組み、そしてグローバルなサプライチェーンの動向によって、ますます左右されるようになっている。
-
ワクチンのサプライチェーンは、医薬品原料、バイアル、ストッパー、包装資材、コールドチェーン用部品、および特殊な製造設備の国境を越えた調達に依存しており、これにより輸入に関連するコスト上昇のリスクが生じている。
-
医薬品原料や生物製剤製造設備に対する米国の関税は、市場全体にコスト上昇の圧力を強めており、製造業者の利益率だけでなく、政府資金による予防接種プログラムの公的調達予算にも影響を及ぼしている。
-
市場全体で見ると、関税の影響は地域によってばらつきがある。米国に生産拠点を構える大手メーカーは対応しやすい立場にある一方、小規模なサプライヤーや輸入に依存するサプライヤーは、利益率への圧力が高まり、競争力が低下している。
商業的影響
-
コストおよび価格面での圧力：投入コストやコンプライアンスコストの上昇が、政府資金によるプログラムの調達経済性に影響を及ぼしており、特に利益率の低い小児用ワクチンや、大量供給を要する公衆衛生イニシアチブにおいてその影響が顕著である。
-
サプライチェーンの変容：企業は、関税リスクを軽減し、供給の回復力を高めるため、ワクチン製造の現地化、地域ごとの充填・包装能力の拡充、およびサプライヤーの多様化を加速させている
-
製造業への投資：関税の動向により、北米および各地域の製造業インフラへの投資や、調達パートナーとの長期的な購入契約が促進されている。
-
競合優位性：多角化され、地域に根差した供給ネットワークを持ち、政府調達における確固たる関係を築いているメーカーは、コストの変動に対処する上でより有利な立場にある
企業情報
ワクチン販売市場は、世界的な大手製薬企業、ワクチン開発の専門企業、新興市場のメーカーが混在しており、各社はプラットフォームの能力、規制当局からの認可、政府との調達関係などを巡って競争を繰り広げている。
GSK、ファイザー、サノフィ、モデルナ、インド・セラム研究所などの大手企業は、パイプラインの拡充、戦略的提携、および高所得国市場と低・中所得国市場の両方への事業展開を通じて、その地位を強化している。
競争は、ますます以下の要素によって特徴づけられるようになっている：
-
mRNA、ウイルスベクター、および無針投与にまたがる次世代プラットフォーム技術の能力
-
政府および多国間調達関係（GaviやPAHOとの供給契約を含む）
-
感染症、腫瘍学、およびパンデミック対策にわたるパイプラインの幅広さ
-
製造の拡張性とコールドチェーン物流能力
本レポートでは、21社の主要企業における競争上の位置づけがどのように変化しているかを分析し、どこで価値が創出されているか、また予測期間中に戦略がどのように変化すると見込まれるかを明らかにしています。
主な疑問への回答
-
2036年までのワクチン販売市場の規模はどの程度になると予測されていますか？
-
どのセグメントや地域が成長を牽引するのでしょうか？
-
次世代ワクチンプラットフォームの進歩は、市場の変遷にどのような影響を与えるのでしょうか？
-
米国の貿易関税は、製造コストや調達予算にどのような影響を与えるのでしょうか？
-
主要企業はどこか、またそれらの地位は今後どのように変化していくのか？
レポートの範囲とデータの対象範囲
-
世界のワクチン販売市場分析
-
2036年までの売上高予測
-
適応症、種類、投与経路、年齢層、および流通経路にわたるセグメントレベルのモデリング
-
5つの地域および26の主要国内市場にわたる地域別・国内市場予測
-
主要21社に関する競合情報
定量的な予測と定性的な戦略分析の両方を含み、技術、競争、政策、サプライチェーンの動向を網羅しています。
セグメンテーションの枠組み
適応別
-
ウイルスワクチン
-
細菌ワクチン
-
がんワクチン
-
アレルギーワクチン
-
その他
タイプ別
-
サブユニットワクチン
-
不活化ワクチン
-
生ワクチン
-
mRNAワクチン
-
ウイルスベクターワクチン
投与経路別
年齢層別
販売チャネル別
対象地域
北米
欧州地
-
ドイツ
-
イギリス
-
フランス
-
イタリア
-
スペイン
-
オランダ
-
スイス
-
その他の欧州地域
アジア太平洋地域
-
日本
-
中国
-
インド
-
オーストラリア
-
シンガポール
-
韓国
-
マレーシア
-
その他のアジア太平洋地域
ラテンアメリカ
-
ブラジル
-
メキシコ
-
アルゼンチン
-
チリ
-
その他のラテンアメリカ
MEA
企業情報 取材範囲
本レポートには、以下を含む21社の主要企業の詳細なプロフィールが掲載されています：
-
アストラゼネカ
-
ババリアン・ノルディック
-
バーラト・バイオテック
-
BioNTech SE
-
CSL
-
第一三共株式会社
-
エマージェント・バイオソリューションズ社
-
GSK plc
-
イノヴィオ・ファーマシューティカルズ
-
メルク・アンド・カンパニー株式会社
-
Moderna, Inc.
-
ノヴァヴァックス
-
パナシア・バイオテック
-
ファイザー社
-
サノフィ
-
Serum Institute of インド Pvt. Ltd.
-
シノバック
-
シノファーム
-
武田薬品工業株式会社
-
タナベファーマ株式会社
-
ヴァルネバSE
各プロフィールには以下の内容が含まれています：
-
事業概要
-
財務および市場における位置づけ
-
製品および技術力
-
戦略的展望
オーダーメイド型インテリジェンス＆カスタマイズ
また、Visiongainでは、お客様それぞれの具体的なご要望に合わせた、オーダーメイド型の情報提供およびアドバイザリー支援も行っています。
これには以下が含まれます：
-
カスタマイズされた市場セグメンテーションと予測
-
競合他社とのベンチマークおよび戦略分析
-
政策および規制の影響評価
-
サプライチェーンおよび調達インテリジェンス
-
関税や地政学的リスクを含むシナリオ・モデリング
ページTOPに戻る
目次
1 レポートの概要
1.1 本調査の目的
1.2 ワクチン販売市場の概要
1.3 本レポートで提供される内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問：
1.6 本レポートの対象読者
1.7 調査方法
1.7.1 市場の定義
1.7.2 市場評価および予測の方法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 二次調査
1.8 よくある質問（FAQ）
1.9 関連するVisiongainレポート
1.10 Visiongainについて
2 概要
3 市場の概要
3.1 主な調査結果
3.2 市場の動向
3.3 影響分析
3.3.1 市場の推進要因
3.3.1.1 ワクチン開発および発売への注力
3.3.1.2 ワクチン技術の進歩
3.3.1.3 低・中所得国（LMICs）における政府資金による国家予防接種計画
3.3.2 市場の抑制要因
3.3.2.1 遠隔地域におけるコールドチェーンのボトルネック
3.3.2.2 CDMOへの充填・仕上げ能力の集中
3.3.3 市場の機会
3.3.3.1 次世代ワクチンへの注目の高まり
3.3.3.2 開発パイプライン候補の早期開発に向けた研究開発投資
3.4 米国の関税：世界のワクチン販売市場に与える影響は？
3.4.1 概要
3.4.2 V字型回復シナリオ
3.4.3 なぜV字型回復なのか？
3.4.3.1 関税による影響
3.4.3.2 市場の動向と需要の回復
3.4.3.3 政策および資金支援
3.4.3.4 回復までの期間
3.4.4 U字型回復シナリオ
3.4.4.1 なぜU字型回復なのか？
3.4.4.2 関税の影響
3.4.4.3 市場の動向と需要の回復
3.4.4.4 政策および資金面での支援
3.4.4.5 回復までの期間
3.4.5 L字型回復シナリオ
3.4.5.1 なぜL字型回復なのか？
3.4.5.2 関税の影響
3.4.5.3 市場の動向と需要の回復
3.4.5.4 政策および資金面での支援
3.4.5.5 回復までの期間
3.4.6 顧客は、短期（2026～2031年）および長期（2026～2036年）の計画において、どのような戦略的考慮事項を織り込むべきか？
3.4.7 米中貿易戦争がワクチン販売市場に与える影響
3.4.8 最も影響を受ける国々は、これらの政策変更によってどのようなプラスおよびマイナスの影響を受ける可能性があるか？
3.5 ポーターの5つの力分析
3.5.1 供給者の交渉力
3.5.2 購入者の交渉力
3.5.3 競合他社間の競争
3.5.4 代替品からの脅威
3.5.5 新規参入者の脅威
3.6 PEST分析
4 ワクチン販売市場分析：タイプ別
4.1 主な調査結果
4.2 タイプ別セグメント：市場魅力度指数
4.3 タイプ別のワクチン売上高の市場規模推推定と予測
4.4 サブユニットワクチン
4.4.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
4.4.2 地域別市場シェア、2026年および2036年（％）
4.5 不活化ワクチン
4.5.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
4.5.2 地域別市場シェア、2026年および2036年（％）
4.6 弱毒生ワクチン
4.6.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
4.6.2 地域別市場シェア、2026年および2036年（％）
4.7 mRNAワクチン
4.7.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
4.7.2 地域別市場シェア、2026年および2036年（％）
4.8 ウイルスベクターワクチン
4.8.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
4.8.2 地域別市場シェア、2026年および2036年（％）
5 ワクチン販売市場の分析：投与経路別
5.1 主な調査結果
5.2 投与経路別セグメント：市場魅力度指数
5.3 投与経路別のワクチン売上市場規模の推計および予測
5.4 経口
5.4.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
5.4.2 地域別市場シェア、2026年および2036年（％）
5.5 非経口
5.5.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
5.5.2 地域別市場シェア、2026年および2036年（％）
5.6 鼻腔投与
5.6.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
5.6.2 地域別市場シェア、2026年および2036年（％）
6 ワクチン販売市場分析：年齢層別
6.1 主な調査結果
6.2 年齢層別：市場魅力度指数
6.3 年齢層別のワクチン売上高の市場規模推計および予測
6.4 成人
6.4.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
6.4.2 地域別市場シェア、2026年および2036年（％）
6.5 小児
6.5.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
6.5.2 地域別市場シェア、2026年および2036年（％）
7 ワクチン販売市場の分析：流通チャネル別
7.1 主な調査結果
7.2 流通チャネル別：市場魅力度指数
7.3 流通チャネル別のワクチン売上市場規模の推計および予測
7.4 病院および小売薬局
7.4.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
7.4.2 地域別市場シェア、2026年および2036年（％）
7.5 政府系供給業者
7.5.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
7.5.2 地域別市場シェア、2026年および2036年（％）
7.6 その他
7.6.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
7.6.2 地域別市場シェア、2026年および2036年（％）
8 ワクチン販売市場の分析：適応症別
8.1 主な調査結果
8.2 適応症セグメント：市場魅力度指数
8.3 適応症別のワクチン売上高の市場規模推計および予測
8.4 ウイルスワクチン
8.4.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
8.4.2 地域別市場シェア、2026年および2036年（％）
8.5 細菌ワクチン
8.5.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
8.5.2 地域別市場シェア、2026年および2036年（％）
8.6 がんワクチン
8.6.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
8.6.2 地域別市場シェア、2026年および2036年（％）
8.7 アレルギーワクチン
8.7.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
8.7.2 地域別市場シェア、2026年および2036年（％）
8.8 その他
8.8.1 地域別市場予測、2026年～2036年（10億米ドル、年平均成長率％）
8.8.2 地域別市場シェア、2026年および2036年（％）
9 ワクチン販売市場の分析：地域別
9.1 主な調査結果
9.2 地域別市場規模の推定と予測
10 北米のワクチン販売市場分析
10.1 主な調査結果
10.2 北米ワクチン販売市場の魅力度指数
10.3 北米ワクチン販売市場：国別、2026年、2031年、2036年（10億米ドル）
10.4 北米ワクチン販売市場規模推定と予測：国別
10.5 北米ワクチン販売市場規模推定と予測：タイプ別
10.6 北米ワクチン販売市場規模推定と予測：投与経路別
10.7 北米ワクチン販売市場規模推定と予測：年齢層別
10.8 北米ワクチン販売市場規模推定と予測：流通チャネル別
10.9 北米ワクチン販売市場規模推定と予測：適応症別
10.10 米国ワクチン販売市場の分析
10.11 カナダワクチン販売市場の分析
11 欧州のワクチン販売市場分析
11.1 主な調査結果
11.2 欧州ワクチン販売市場の魅力度指数
11.3 欧州ワクチン販売市場：国別、2026年、2031年、2036年（10億米ドル）
11.4 欧州ワクチン販売市場規模推定と予測：国別
11.5 欧州ワクチン販売市場規模推定と予測：タイプ別
11.6 欧州ワクチン販売市場規模推定と予測：投与経路別
11.7 欧州ワクチン販売市場規模推定と予測：年齢層別
11.8 欧州ワクチン販売市場規模推定と予測：流通チャネル別
11.9 欧州ワクチン販売市場規模推定と予測：適応症別
11.10 ドイツのワクチン販売市場分析
11.11 英国のワクチン販売市場分析
11.12 フランスのワクチン販売市場分析
11.13 イタリアのワクチン販売市場分析
11.14 スペインのワクチン販売市場分析
11.15 オランダのワクチン販売市場分析
11.16 スイスのワクチン販売市場分析
11.17 その他の欧州地域のワクチン販売市場分析
12 アジア太平洋地域のワクチン販売市場分析
12.1 主な調査結果
12.2 アジア太平洋地域のワクチン販売市場の魅力度指数
12.3 アジア太平洋地域のワクチン販売市場：国別、2026年、2031年、2036年（10億米ドル）
12.4 アジア太平洋地域のワクチン販売市場規模推定と予測：国別
12.5 アジア太平洋地域のワクチン販売市場規模推定と予測：タイプ別
12.6 アジア太平洋地域のワクチン販売市場規模推定と予測：投与経路別
12.7 アジア太平洋地域のワクチン販売市場規模推定と予測：年齢層別
12.8 アジア太平洋地域のワクチン販売市場規模推定と予測：流通チャネル別
12.9 アジア太平洋地域のワクチン販売市場規模推定と予測：適応症別
12.10 日本のワクチン販売市場分析
12.11 中国のワクチン販売市場分析
12.12 インドのワクチン販売市場分析
12.13 オーストラリアのワクチン販売市場分析
12.14 韓国のワクチン販売市場分析
12.15 シンガポールのワクチン販売市場分析
12.16 マレーシアのワクチン販売市場分析
12.17 その他のアジア太平洋地域のワクチン販売市場分析
13 ラテンアメリカのワクチン販売市場分析
13.1 主な調査結果
13.2 ラテンアメリカのワクチン販売市場の魅力度指数
13.3 ラテンアメリカのワクチン販売市場：国別、2026年、2031年、2036年（10億米ドル）
13.4 ラテンアメリカのワクチン販売市場規模推定と予測：国別
13.5 ラテンアメリカのワクチン販売市場規模推定と予測：タイプ別
13.6 ラテンアメリカのワクチン販売市場規模推定と予測：投与経路別
13.7 ラテンアメリカのワクチン販売市場規模推定と予測：年齢層別
13.8 ラテンアメリカのワクチン販売市場規模推定と予測：流通チャネル別
13.9 ラテンアメリカのワクチン販売市場規模推定と予測：適応症別
13.10 ブラジルのワクチン販売市場分析
13.11 メキシコのワクチン販売市場分析
13.12 アルゼンチンのワクチン販売市場分析
13.13 チリのワクチン販売市場分析
13.14 その他のラテンアメリカ地域のワクチン販売市場分析
14 MEAワクチン販売市場の分析
14.1 主な調査結果
14.2 MEAワクチン販売市場の魅力度指数
14.3 MEAワクチン販売市場：国別、2026年、2031年、2036年（10億米ドル）
14.4 MEAワクチン販売市場規模推定と予測：国別
14.5 MEAワクチン販売市場規模推定と予測：タイプ別
14.6 MEAワクチン販売市場規模推定と予測：投与経路別
14.7 MEAワクチン販売市場規模推定と予測：年齢層別
14.8 MEAワクチン販売市場規模推定と予測：流通チャネル別
14.9 MEA ワクチン販売市場規模推定と予測：適応症別
14.10 GCC ワクチン販売市場分析
14.11 南アフリカ ワクチン販売市場分析
14.12 その他のMEA地域 ワクチン販売市場分析
15 主要企業の概要
15.1 ババリアン・ノルディック
15.1.1 企業概要
15.1.2 会社概要
15.1.3 財務分析
15.1.3.1 純売上高（2021年～2025年）
15.1.3.2 研究開発費（2021年～2025年）
15.1.3.3 地域別市場シェア（2025年）
15.1.4 製品ベンチマーク
15.1.5 戦略的展望
15.2 バーラト・バイオテック
15.2.1 企業概要
15.2.2 会社概要
15.2.3 製品ベンチマーク
15.2.4 戦略的展望
15.3 CSL
15.3.1 企業概要
15.3.2 会社概要
15.3.3 財務分析
15.3.3.1 純売上高（2021年～2025年）
15.3.3.2 研究開発費（2021年～2025年）
15.3.3.3 地域別市場シェア（2025年）
15.3.4 製品ベンチマーク
15.3.5 戦略的展望
15.4 Emergent BioSolutions Inc.
15.4.1 企業概要
15.4.2 会社概要
15.4.3 財務分析
15.4.3.1 純売上高（2021年～2025年）
15.4.3.2 研究開発（R&D）（2021年～2025年）
15.4.4 製品ベンチマーク
15.4.5 戦略的展望
15.5 GSK plc
15.5.1 企業概要
15.5.2 会社概要
15.5.3 財務分析
15.5.3.1 純売上高（2021年～2025年）
15.5.3.2 研究開発（R&D）（2021年～2025年）
15.5.3.3 地域別市場シェア（2025年）
15.5.4 製品ベンチマーク
15.5.5 戦略的展望
15.6 INOVIO Pharmaceuticals
15.6.1 企業概要
15.6.2 会社概要
15.6.3 製品ベンチマーク
15.7 メルク・アンド・カンパニー（Merck & Co., Inc.）
15.7.1 企業概要
15.7.2 会社概要
15.7.3 財務分析
15.7.3.1 純売上高、2021年～2025年
15.7.3.2 研究開発費（2021年～2025年）
15.7.3.3 地域別市場シェア（2025年）
15.7.4 製品ベンチマーク
15.8 田辺製薬株式会社
15.8.1 企業概要
15.8.2 会社概要
15.8.3 製品ベンチマーキング
15.9 モデルナ社
15.9.1 企業概要
15.9.2 会社概要
15.9.3 財務分析
15.9.3.1 純売上高（2021年～2025年）
15.9.3.2 研究開発費（2021年～2025年）
15.9.4 製品ベンチマーク
15.9.5 戦略的展望
15.10 ノババックス
15.10.1 企業概要
15.10.2 会社概要
15.10.3 製品ベンチマーク
15.10.4 戦略的展望
15.11 パナセア・バイオテック
15.11.1 企業概要
15.11.2 会社概要
15.11.3 製品ベンチマーク
15.12 ファイザー社
15.12.1 企業概要
15.12.2 会社概要
15.12.3 財務分析
15.12.3.1 純売上高（2021年～2025年）
15.12.3.2 研究開発費（2021年～2025年）
15.12.4 製品ベンチマーク
15.12.5 戦略的展望
15.13 サノフィ
15.13.1 企業概要
15.13.2 企業概要
15.13.3 財務分析
15.13.3.1 純売上高（2021年～2025年）
15.13.3.2 研究開発（R&D）（2021年～2025年）
15.13.3.3 地域別市場シェア（2025年）
15.13.4 製品ベンチマーク
15.13.5 戦略的展望
15.14 セラム・インスティテュート・オブ・インディア（Serum Institute of India Pvt. Ltd.）
15.14.1 企業概要
15.14.2 会社概要
15.14.3 製品ベンチマーク
15.14.4 戦略的展望
15.15 アストラゼネカ
15.15.1 企業概要
15.15.2 会社概要
15.15.3 財務分析
15.15.3.1 純売上高（2021年～2025年）
15.15.3.2 研究開発費（2021年～2025年）
15.15.3.3 地域別市場シェア（2025年）
15.15.4 製品ベンチマーク
15.16 シノファーム
15.16.1 企業概要
15.16.2 会社概要
15.16.3 製品ベンチマーキング
15.17 シノバック
15.17.1 企業概要
15.17.2 会社概要
15.17.3 製品ベンチマーク
15.17.4 戦略的展望
15.18 武田薬品工業株式会社
15.18.1 企業概要
15.18.2 会社概要
15.18.3 財務分析
15.18.3.1 純売上高（2021年～2025年）
15.18.3.2 研究開発費（2021年～2025年）
15.18.3.3 地域別市場シェア（2025年）
15.18.4 製品ベンチマーク
15.18.5 戦略的展望
15.19 第一三共株式会社
15.19.1 企業概要
15.19.2 会社概要
15.19.3 製品ベンチマーク
15.20 ヴァルネバSE
15.20.1 企業概要
15.20.2 会社概要
15.20.3 財務分析
15.20.3.1 純売上高（2021年～2025年）
15.20.3.2 研究開発費（2021年～2025年）
15.20.4 製品ベンチマーク
15.20.5 戦略的展望
15.21 BioNTech SE
15.21.1 企業概要
15.21.2 会社概要
15.21.3 財務分析
15.21.3.1 純売上高（2021年～2025年）
15.21.3.2 研究開発費（R&D）、2021年～2025年
15.21.3.3 事業セグメント別市場シェア、2025年
15.21.4 製品ベンチマーキング
15.21.5 戦略的展望
16 結論と提言
16.1 Visiongainによる総括
16.2 市場関係者への提言
ページTOPに戻る
図表リスト
List of Tables
Table 1 Vaccine Sales Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 5 Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 6 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Inactivated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 Live Attenuated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 mRNA Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 12 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Nasal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 16 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Paediatric Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 19 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Government Suppliers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 23 Viral Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 Bacterial Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Cancer Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Allergy Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 North America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 North America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 31 North America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 32 North America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 33 North America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 34 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 35 U.S. Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 36 Canada Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 37 Europe Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 39 Europe Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 40 Europe Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 41 Europe Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 42 Europe Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 43 Germany Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 44 UK Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 45 France Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 46 Italy Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 47 Spain Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 48 The Netherlands Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 49 Switzerland Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 50 Rest of Europe Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 51 Asia Pacific Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Asia Pacific Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 53 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 54 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 55 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 56 Asia Pacific Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 57 Japan Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 58 China Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 59 India Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 60 Australia Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 61 South Korea Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 62 Singapore Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 63 Malaysia Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 65 Latin America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 67 Latin America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 68 Latin America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 69 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 70 Latin America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 71 Brazil Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 72 Mexico Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 73 Argentina Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 74 Chile Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 75 Rest of Latin America Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 76 MEA Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 MEA Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 78 MEA Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 79 MEA Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 80 MEA Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 81 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 82 GCC Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 83 South Africa Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 84 Rest of MEA Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 85 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Bavarian Nordic: Product Benchmarking
Table 87 Bavarian Nordic: Strategic Outlook
Table 88 Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Bharat Biotech: Product Benchmarking
Table 90 Bharat Biotech: Strategic Outlook
Table 91 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 CSL: Product Benchmarking
Table 93 CSL: Strategic Outlook
Table 94 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Emergent BioSolutions Inc.: Product Benchmarking
Table 96 Emergent BioSolutions Inc.: Strategic Outlook
Table 97 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 GSK plc: Product Benchmarking
Table 99 GSK plc: Strategic Outlook
Table 100 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 INOVIO Pharmaceuticals: Product Benchmarking
Table 102 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Merck & Co., Inc.: Product Benchmarking
Table 104 Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Tanabe Pharma Corporation: Product Benchmarking
Table 106 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Moderna, Inc.: Product Benchmarking
Table 108 Moderna, Inc.: Strategic Outlook
Table 109 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Novavax: Product Benchmarking
Table 111 Novavax: Strategic Outlook
Table 112 Panacea Biotec.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Panacea Biotec: Product Benchmarking
Table 114 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Pfizer Inc.: Product Benchmarking
Table 116 Pfizer Inc.: Strategic Outlook
Table 117 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Sanofi: Product Benchmarking
Table 119 Sanofi: Strategic Outlook
Table 120 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 122 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 123 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 AstraZeneca: Product Benchmarking
Table 125 Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Sinopharm: Product Benchmarking
Table 127 SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 SINOVAC: Product Benchmarking
Table 129 SINOVAC: Strategic Outlook
Table 130 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 132 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 133 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
Table 135 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Valneva SE: Product Benchmarking
Table 137 Valneva SE: Strategic Outlook
Table 138 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 BioNTech SE: Product Benchmarking
Table 140 BioNTech SE: Strategic Outlook
List of Figures
Figure 1 Vaccine Sales Market Segmentation
Figure 2 Vaccine Sales Market by Type: Market Attractiveness Index
Figure 3 Vaccine Sales Market by Route of Administration: Market Attractiveness Index
Figure 4 Vaccine Sales Market by Age Group: Market Attractiveness Index
Figure 5 Vaccine Sales Market by Distribution Channel: Market Attractiveness Index
Figure 6 Vaccine Sales Market by Indication: Market Attractiveness Index
Figure 7 Vaccine Sales Market Attractiveness Index by Region
Figure 8 Vaccine Sales Market: Market Dynamics
Figure 9 Vaccine Sales Market: Impact Analysis
Figure 10 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 11 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 12 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 13 Short Term & Long Term Planning
Figure 14 Impact of U.S. and China Trade War
Figure 15 Most Impacted Countries
Figure 16 Vaccine Sales Market: Porter’s Five Forces Analysis
Figure 17 Vaccine Sales Market: PEST Analysis
Figure 18 Vaccine Sales Market Attractiveness Index by Type
Figure 19 Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 20 Vaccine Sales Market Share Forecast by Type, 2026, 2031, 2036 (%)
Figure 21 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 22 Subunit Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 23 Inactivated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 24 Inactivated Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 25 Live Attenuated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 26 Live Attenuated Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 27 mRNA Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 28 mRNA Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 29 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 30 Viral Vector Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 31 Vaccine Sales Market Attractiveness Index by Type
Figure 32 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 33 Vaccine Sales Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 34 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 35 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 36 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 37 Parenteral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 38 Nasal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 39 Nasal Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 40 Vaccine Sales Market Attractiveness Index by Age Group
Figure 41 Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 42 Vaccine Sales Market Share Forecast by Age Group, 2026, 2031, 2036 (%)
Figure 43 Adult Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 44 Adult Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 45 Paediatric Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 46 Paediatric Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 47 Vaccine Sales Market Attractiveness Index by Distribution Channel
Figure 48 Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 49 Vaccine Sales Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
Figure 50 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 51 Hospital & Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 52 Government Suppliers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 53 Government Suppliers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 54 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 55 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 56 Vaccine Sales Market Attractiveness Index by Indication
Figure 57 Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 58 Vaccine Sales Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 59 Viral Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 60 Viral Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 61 Bacterial Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 62 Bacterial Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 63 Cancer Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 64 Cancer Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 65 Allergy Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 66 Allergy Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 67 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 68 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 69 Vaccine Sales Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 70 Vaccine Sales Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 71 Vaccine Sales Market by Region, 2026-2036 (US$ Mn)
Figure 72 North America Vaccine Sales Market Attractiveness Index
Figure 73 North America Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 74 North America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 75 North America Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 76 North America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 77 North America Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 78 North America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 79 North America Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 80 North America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 81 North America Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 82 North America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 83 North America Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 84 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 85 North America Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 86 U.S. Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 87 Canada Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 88 Europe Vaccine Sales Market Attractiveness Index
Figure 89 Europe Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 90 Europe Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 91 Europe Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 92 Europe Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 93 Europe Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 94 Europe Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 95 Europe Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 96 Europe Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 97 Europe Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 98 Europe Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 99 Europe Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 100 Europe Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 101 Europe Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 102 Germany Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 103 UK Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 104 France Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 105 Italy Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 106 Spain Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 107 The Netherlands Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 108 Switzerland Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 109 Rest of Europe Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 110 Asia Pacific Vaccine Sales Market Attractiveness Index
Figure 111 Asia Pacific Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 112 Asia Pacific Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 113 Asia Pacific Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 114 Asia Pacific Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 115 Asia Pacific Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 116 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 117 Asia Pacific Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 118 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 119 Asia Pacific Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 120 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 121 Asia Pacific Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 122 Asia Pacific Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 123 Asia Pacific Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 124 Japan Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 125 China Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 126 India Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 127 Australia Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 128 South Korea Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 129 Singapore Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 130 Malaysia Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 131 Rest of Asia Pacific Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 132 Latin America Vaccine Sales Market Attractiveness Index
Figure 133 Latin America Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 134 Latin America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 135 Latin America Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 136 Latin America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 137 Latin America Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 138 Latin America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 139 Latin America Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 140 Latin America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 141 Latin America Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 142 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 143 Latin America Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 144 Latin America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 145 Latin America Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 146 Brazil Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 147 Mexico Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 148 Argentina Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 149 Chile Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 150 Rest of Latin America Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 151 MEA Vaccine Sales Market Attractiveness Index
Figure 152 MEA Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 153 MEA Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 154 MEA Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 155 MEA Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 156 MEA Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 157 MEA Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 158 MEA Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 159 MEA Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 160 MEA Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 161 MEA Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 162 MEA Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 163 MEA Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 164 MEA Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 165 GCC Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 166 South Africa Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 167 Rest of MEA Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 168 Bavarian Nordic: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 169 Bavarian Nordic: R&D, 2021-2025 (US$ Million, AGR %)
Figure 170 Bavarian Nordic: Regional Market Shares, 2025
Figure 171 CSL: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 172 CSL: R&D, 2021-2025 (US$ Million, AGR %)
Figure 173 CSL: Regional Market Shares, 2025
Figure 174 Emergent BioSolutions Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 175 Emergent BioSolutions Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 176 GSK plc: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 177 GSK plc: R&D, 2021-2025 (US$ Million, AGR %)
Figure 178 GSK plc: Regional Market Shares, 2025
Figure 179 Merck & Co., Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 180 Merck & Co., Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 181 Merck & Co., Inc.: Regional Market Shares, 2025
Figure 182 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 183 Moderna, Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 184 Pfizer Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 185 Pfizer Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 186 Sanofi: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 187 Sanofi: R&D, 2021-2025 (US$ Million, AGR %)
Figure 188 Sanofi: Regional Market Shares, 2025
Figure 189 AstraZeneca: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 190 AstraZeneca: R&D, 2021-2025 (US$ Million, AGR %)
Figure 191 AstraZeneca: Regional Market Shares, 2025
Figure 192 Takeda Pharmaceutical Company Limited: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 193 Takeda Pharmaceutical Company Limited: R&D, 2021-2025 (US$ Million, AGR %)
Figure 194 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2025
Figure 195 Valneva SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 196 Valneva SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 197 BioNTech SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 198 BioNTech SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 199 BioNTech SE: Business Segment Market Shares (%), 2025
ページTOPに戻る
Summary
Description
Visiongain has published a new report, Vaccine Sales Market Report 2026-2036, providing a comprehensive analysis of the global vaccine sales market, including market size, growth drivers, competitive positioning, and revenue forecasts across indication, type, route of administration, age group, and distribution channel segments.
The global vaccine sales market is valued at US$76.40bn in 2026 and is forecast to reach US$141.40bn by 2036, at a CAGR of 6.3% over the forecast period.
This growth is driven by rising infectious disease prevalence, expanding government-funded immunisation programmes in low- and middle-income countries, and accelerating investment in next-generation vaccine platforms including mRNA, viral vector, and needle-free delivery technologies.
Technological Innovation Driving Market Expansion
Platform-based vaccine technologies including mRNA, viral vector, and DNA approaches are expanding vaccine pipelines and supporting product development across multiple disease areas. Candidates such as mRNA-4157 (Moderna and Merck) demonstrate growing mRNA application in oncology, while ongoing work in HIV, Nipah virus, and pandemic influenza reflects continued diversification of the vaccine development landscape.
Innovation in formulation and delivery is also supporting wider adoption. Intranasal and oral vaccines simplify administration and improve patient acceptance, particularly in paediatric populations. Emerging needle-free technologies including dissolvable microarray patches are being developed to reduce logistical complexity, minimise cold-chain dependence, and support self-administration across low-resource settings.
In December 2025, CEPI committed up to US$54.3 million to support a Phase 3 trial of Moderna’s mRNA-based H5 pandemic influenza vaccine candidate (mRNA-1018), advancing the first mRNA influenza vaccine into pivotal-stage development and strengthening the commercial pipeline for next-generation vaccine platforms.
Trade, Policy & Supply Chain Dynamics
-
The vaccine sales market is increasingly shaped by U.S. trade tariff policies, public procurement frameworks, and global supply chain dynamics.
-
Vaccine supply chains rely on cross-border sourcing of pharmaceutical ingredients, vials, stoppers, packaging materials, cold-chain components, and specialised manufacturing equipment, creating exposure to import-related cost escalation.
-
U.S. tariffs on pharmaceutical inputs and biologics manufacturing equipment are increasing cost pressures across the market, affecting both producer margins and public procurement budgets for government-funded immunisation programmes.
-
Tariff exposure is uneven across the market: larger manufacturers with U.S.-based facilities are better positioned to adapt, while smaller and import-dependent suppliers face greater margin pressure and reduced competitiveness.
Commercial Impact
-
Cost and pricing pressure: Rising input and compliance costs are affecting procurement economics for government-funded programmes, particularly for low-margin paediatric vaccines and high-volume public health initiatives
-
Supply chain shifts: Companies are accelerating localisation of vaccine manufacturing, regional fill-finish capacity, and supplier diversification to reduce tariff exposure and improve supply resilience
-
Manufacturing investment: Tariff dynamics are encouraging investment in North American and regional manufacturing infrastructure and longer-term purchasing agreements with procurement partners
-
Competitive positioning: Manufacturers with diversified, regionally anchored supply networks and established government procurement relationships are better positioned to manage cost volatility
Company Intelligence
The vaccine sales market is characterised by a mix of global pharmaceutical leaders, specialist vaccine developers, and emerging-market manufacturers competing across platform capability, regulatory credentials, and government procurement relationships.
Leading companies including GSK, Pfizer, Sanofi, Moderna, and Serum Institute of India are strengthening their positions through pipeline expansion, strategic partnerships, and geographic reach across both high-income and low- and middle-income markets.
Competition is increasingly defined by:
-
Next-generation platform technology capability across mRNA, viral vector, and needle-free delivery
-
Government and multilateral procurement relationships including Gavi and PAHO supply agreements
-
Pipeline breadth across infectious disease, oncology, and pandemic preparedness
-
Manufacturing scalability and cold-chain distribution capability
This report analyses how competitive positioning is evolving across 21 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.
Key Questions Answered
-
What is the projected size of the vaccine sales market by 2036?
-
Which segments and regions will drive growth?
-
How will advances in next-generation vaccine platforms shape market evolution?
-
What is the impact of U.S. trade tariffs on manufacturing costs and procurement budgets?
-
Who are the leading companies and how will their positions evolve?
Report Scope and Data Coverage
-
Global vaccine sales market analysis
-
Revenue forecasts to 2036
-
Segment-level modelling across indication, type, route of administration, age group, and distribution channel
-
Regional and national market forecasts across five regions and 26 leading national markets
-
Competitive intelligence on 21 leading companies
Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.
Segmentation Framework
By Indication
-
Viral Vaccines
-
Bacterial Vaccines
-
Cancer Vaccines
-
Allergy Vaccines
-
Others
By Type
-
Subunit Vaccines
-
Inactivated Vaccines
-
Live Attenuated Vaccines
-
mRNA Vaccines
-
Viral Vector Vaccines
By Route of Administration
By Age Group
By Distribution Channel
-
Hospital & Retail Pharmacies
-
Government Suppliers
-
Others
Geographic Coverage
North America
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
The Netherlands
-
Switzerland
-
Rest of Europe
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Singapore
-
South Korea
-
Malaysia
-
Rest of Asia Pacific
Latin America
-
Brazil
-
Mexico
-
Argentina
-
Chile
-
Rest of Latin America
MEA
-
GCC
-
South Africa
-
Rest of MEA
Company Intelligence Coverage
This report includes detailed profiles of 21 leading companies, including:
-
AstraZeneca
-
Bavarian Nordic
-
Bharat Biotech
-
BioNTech SE
-
CSL
-
DAIICHI SANKYO COMPANY, LIMITED
-
Emergent BioSolutions Inc.
-
GSK plc
-
INOVIO Pharmaceuticals
-
Merck & Co., Inc.
-
Moderna, Inc.
-
Novavax
-
Panacea Biotec
-
Pfizer Inc.
-
Sanofi
-
Serum Institute of India Pvt. Ltd.
-
SINOVAC
-
SINOPHARM
-
Takeda Pharmaceutical Company Limited
-
Tanabe Pharma Corporation
-
Valneva SE
Each profile includes:
-
Business overview
-
Financial and market positioning
-
Product and technology capabilities
-
Strategic outlook
Bespoke Intelligence & Customisation
Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.
This includes:
-
Custom market segmentation and forecasts
-
Competitive benchmarking and strategy analysis
-
Policy and regulatory impact assessment
-
Supply chain and sourcing intelligence
-
Scenario modelling including tariffs and geopolitical risk
ページTOPに戻る
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Vaccine Sales Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Focus on Vaccine Development and Launches
3.3.1.2 Advancement in Vaccine Technology
3.3.1.3 Government-funded National Immunisation Plans in LMICs
3.3.2 Market Restraining Factors
3.3.2.1 Cold-Chain Bottlenecks in Remote Regions
3.3.2.2 Concentration of Fill-finish Capacity in CDMOs
3.3.3 Market Opportunities
3.3.3.1 Growing Focus on Next-Generation Vaccines
3.3.3.2 R&D Investments to Accelerate Development of Pipeline Candidates
3.4 U.S. Tariffs: What’s the Impact on Global Vaccine Sales Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.7 Impact of U.S. and China Trade War on Vaccine Sales Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
4 Vaccine Sales Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Vaccine Sales Market Size Estimation and Forecast by Type
4.4 Subunit Vaccines
4.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 Inactivated
4.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.6 Live Attenuated
4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 mRNA Vaccines
4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.7.2 Market Share by Region, 2026 & 2036 (%)
4.8 Viral Vector Vaccines
4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.8.2 Market Share by Region, 2026 & 2036 (%)
5 Vaccine Sales Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment: Market Attractiveness Index
5.3 Vaccine Sales Market Size Estimation and Forecast by Route of Administration
5.4 Oral
5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Parenteral
5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Nasal
5.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.6.2 Market Share by Region, 2026 & 2036 (%)
6 Vaccine Sales Market Analysis by Age Group
6.1 Key Findings
6.2 Age Group Segment: Market Attractiveness Index
6.3 Vaccine Sales Market Size Estimation and Forecast by Age Group
6.4 Adult
6.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Paediatric
6.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.5.2 Market Share by Region, 2026 & 2036 (%)
7 Vaccine Sales Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital & Retail Pharmacies
7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Government Suppliers
7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Others
7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.6.2 Market Share by Region, 2026 & 2036 (%)
8 Vaccine Sales Market Analysis by Indication
8.1 Key Findings
8.2 Indication Segment: Market Attractiveness Index
8.3 Vaccine Sales Market Size Estimation and Forecast by Indication
8.4 Viral Vaccines
8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Bacterial Vaccines
8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Cancer Vaccines
8.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.6.2 Market Share by Region, 2026 & 2036 (%)
8.7 Allergy Vaccines
8.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.7.2 Market Share by Region, 2026 & 2036 (%)
8.8 Others
8.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.8.2 Market Share by Region, 2026 & 2036 (%)
9 Vaccine Sales Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
10 North America Vaccine Sales Market Analysis
10.1 Key Findings
10.2 North America Vaccine Sales Market Attractiveness Index
10.3 North America Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
10.4 North America Vaccine Sales Market Size Estimation and Forecast by Country
10.5 North America Vaccine Sales Market Size Estimation and Forecast by Type
10.6 North America Vaccine Sales Market Size Estimation and Forecast by Route of Administration
10.7 North America Vaccine Sales Market Size Estimation and Forecast by Age Group
10.8 North America Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
10.9 North America Vaccine Sales Market Size Estimation and Forecast by Indication
10.10 U.S. Vaccine Sales Market Analysis
10.11 Canada Vaccine Sales Market Analysis
11 Europe Vaccine Sales Market Analysis
11.1 Key Findings
11.2 Europe Vaccine Sales Market Attractiveness Index
11.3 Europe Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 Europe Vaccine Sales Market Size Estimation and Forecast by Country
11.5 Europe Vaccine Sales Market Size Estimation and Forecast by Type
11.6 Europe Vaccine Sales Market Size Estimation and Forecast by Route of Administration
11.7 Europe Vaccine Sales Market Size Estimation and Forecast by Age Group
11.8 Europe Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
11.9 Europe Vaccine Sales Market Size Estimation and Forecast by Indication
11.10 Germany Vaccine Sales Market Analysis
11.11 UK Vaccine Sales Market Analysis
11.12 France Vaccine Sales Market Analysis
11.13 Italy Vaccine Sales Market Analysis
11.14 Spain Vaccine Sales Market Analysis
11.15 The Netherlands Vaccine Sales Market Analysis
11.16 Switzerland Vaccine Sales Market Analysis
11.17 Rest of Europe Vaccine Sales Market Analysis
12 Asia Pacific Vaccine Sales Market Analysis
12.1 Key Findings
12.2 Asia Pacific Vaccine Sales Market Attractiveness Index
12.3 Asia Pacific Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Country
12.5 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Type
12.6 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Route of Administration
12.7 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Age Group
12.8 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
12.9 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Indication
12.10 Japan Vaccine Sales Market Analysis
12.11 China Vaccine Sales Market Analysis
12.12 India Vaccine Sales Market Analysis
12.13 Australia Vaccine Sales Market Analysis
12.14 South Korea Vaccine Sales Market Analysis
12.15 Singapore Vaccine Sales Market Analysis
12.16 Malaysia Vaccine Sales Market Analysis
12.17 Rest of Asia Pacific Vaccine Sales Market Analysis
13 Latin America Vaccine Sales Market Analysis
13.1 Key Findings
13.2 Latin America Vaccine Sales Market Attractiveness Index
13.3 Latin America Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 Latin America Vaccine Sales Market Size Estimation and Forecast by Country
13.5 Latin America Vaccine Sales Market Size Estimation and Forecast by Type
13.6 Latin America Vaccine Sales Market Size Estimation and Forecast by Route of Administration
13.7 Latin America Vaccine Sales Market Size Estimation and Forecast by Age Group
13.8 Latin America Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
13.9 Latin America Vaccine Sales Market Size Estimation and Forecast by Indication
13.10 Brazil Vaccine Sales Market Analysis
13.11 Mexico Vaccine Sales Market Analysis
13.12 Argentina Vaccine Sales Market Analysis
13.13 Chile Vaccine Sales Market Analysis
13.14 Rest of Latin America Vaccine Sales Market Analysis
14 MEA Vaccine Sales Market Analysis
14.1 Key Findings
14.2 MEA Vaccine Sales Market Attractiveness Index
14.3 MEA Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
14.4 MEA Vaccine Sales Market Size Estimation and Forecast by Country
14.5 MEA Vaccine Sales Market Size Estimation and Forecast by Type
14.6 MEA Vaccine Sales Market Size Estimation and Forecast by Route of Administration
14.7 MEA Vaccine Sales Market Size Estimation and Forecast by Age Group
14.8 MEA Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
14.9 MEA Vaccine Sales Market Size Estimation and Forecast by Indication
14.10 GCC Vaccine Sales Market Analysis
14.11 South Africa Vaccine Sales Market Analysis
14.12 Rest of MEA Vaccine Sales Market Analysis
15 Company Profiles
15.1 Bavarian Nordic
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2021-2025
15.1.3.2 R&D, 2021-2025
15.1.3.3 Regional Market Shares, 2025
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Bharat Biotech
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.2.4 Strategic Outlook
15.3 CSL
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2021-2025
15.3.3.2 R&D, 2021-2025
15.3.3.3 Regional Market Shares, 2025
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Emergent BioSolutions Inc.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2021-2025
15.4.3.2 R&D, 2021-2025
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 GSK plc
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2021-2025
15.5.3.2 R&D, 2021-2025
15.5.3.3 Regional Market Shares, 2025
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 INOVIO Pharmaceuticals
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Product Benchmarking
15.7 Merck & Co., Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2021-2025
15.7.3.2 R&D, 2021-2025
15.7.3.3 Regional Market Shares, 2025
15.7.4 Product Benchmarking
15.8 Tanabe Pharma Corporation
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.9 Moderna, Inc.
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2021-2025
15.9.3.2 R&D, 2021-2025
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 Novavax
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Product Benchmarking
15.10.4 Strategic Outlook
15.11 Panacea Biotec
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.12 Pfizer Inc.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2021-2025
15.12.3.2 R&D, 2021-2025
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 Sanofi
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2021-2025
15.13.3.2 R&D, 2021-2025
15.13.3.3 Regional Market Shares, 2025
15.13.4 Product Benchmarking
15.13.5 Strategic Outlook
15.14 Serum Institute of India Pvt. Ltd.
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Product Benchmarking
15.14.4 Strategic Outlook
15.15 AstraZeneca
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2021-2025
15.15.3.2 R&D, 2021-2025
15.15.3.3 Regional Market Shares, 2025
15.15.4 Product Benchmarking
15.16 Sinopharm
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Product Benchmarking
15.17 SINOVAC
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Product Benchmarking
15.17.4 Strategic Outlook
15.18 Takeda Pharmaceutical Company Limited
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Financial Analysis
15.18.3.1 Net Revenue, 2021-2025
15.18.3.2 R&D, 2021-2025
15.18.3.3 Regional Market Shares, 2025
15.18.4 Product Benchmarking
15.18.5 Strategic Outlook
15.19 DAIICHI SANKYO COMPANY, LIMITED
15.19.1 Company Snapshot
15.19.2 Company Overview
15.19.3 Product Benchmarking
15.20 Valneva SE
15.20.1 Company Snapshot
15.20.2 Company Overview
15.20.3 Financial Analysis
15.20.3.1 Net Revenue, 2021-2025
15.20.3.2 R&D, 2021-2025
15.20.4 Product Benchmarking
15.20.5 Strategic Outlook
15.21 BioNTech SE
15.21.1 Company Snapshot
15.21.2 Company Overview
15.21.3 Financial Analysis
15.21.3.1 Net Revenue, 2021-2025
15.21.3.2 R&D, 2021-2025
15.21.3.3 Business Segment Market Shares, 2025
15.21.4 Product Benchmarking
15.21.5 Strategic Outlook
16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players
ページTOPに戻る
List of Tables/Graphs
List of Tables
Table 1 Vaccine Sales Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 5 Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 6 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Inactivated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 Live Attenuated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 mRNA Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 12 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Nasal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 16 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Paediatric Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 19 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Government Suppliers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 23 Viral Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 Bacterial Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Cancer Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Allergy Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 North America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 North America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 31 North America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 32 North America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 33 North America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 34 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 35 U.S. Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 36 Canada Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 37 Europe Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 39 Europe Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 40 Europe Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 41 Europe Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 42 Europe Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 43 Germany Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 44 UK Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 45 France Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 46 Italy Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 47 Spain Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 48 The Netherlands Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 49 Switzerland Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 50 Rest of Europe Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 51 Asia Pacific Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Asia Pacific Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 53 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 54 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 55 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 56 Asia Pacific Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 57 Japan Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 58 China Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 59 India Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 60 Australia Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 61 South Korea Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 62 Singapore Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 63 Malaysia Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 65 Latin America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 67 Latin America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 68 Latin America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 69 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 70 Latin America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 71 Brazil Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 72 Mexico Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 73 Argentina Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 74 Chile Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 75 Rest of Latin America Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 76 MEA Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 MEA Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 78 MEA Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 79 MEA Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 80 MEA Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 81 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 82 GCC Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 83 South Africa Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 84 Rest of MEA Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 85 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Bavarian Nordic: Product Benchmarking
Table 87 Bavarian Nordic: Strategic Outlook
Table 88 Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Bharat Biotech: Product Benchmarking
Table 90 Bharat Biotech: Strategic Outlook
Table 91 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 CSL: Product Benchmarking
Table 93 CSL: Strategic Outlook
Table 94 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Emergent BioSolutions Inc.: Product Benchmarking
Table 96 Emergent BioSolutions Inc.: Strategic Outlook
Table 97 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 GSK plc: Product Benchmarking
Table 99 GSK plc: Strategic Outlook
Table 100 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 INOVIO Pharmaceuticals: Product Benchmarking
Table 102 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Merck & Co., Inc.: Product Benchmarking
Table 104 Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Tanabe Pharma Corporation: Product Benchmarking
Table 106 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Moderna, Inc.: Product Benchmarking
Table 108 Moderna, Inc.: Strategic Outlook
Table 109 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Novavax: Product Benchmarking
Table 111 Novavax: Strategic Outlook
Table 112 Panacea Biotec.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Panacea Biotec: Product Benchmarking
Table 114 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Pfizer Inc.: Product Benchmarking
Table 116 Pfizer Inc.: Strategic Outlook
Table 117 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Sanofi: Product Benchmarking
Table 119 Sanofi: Strategic Outlook
Table 120 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 122 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 123 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 AstraZeneca: Product Benchmarking
Table 125 Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Sinopharm: Product Benchmarking
Table 127 SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 SINOVAC: Product Benchmarking
Table 129 SINOVAC: Strategic Outlook
Table 130 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 132 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 133 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
Table 135 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Valneva SE: Product Benchmarking
Table 137 Valneva SE: Strategic Outlook
Table 138 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 BioNTech SE: Product Benchmarking
Table 140 BioNTech SE: Strategic Outlook
List of Figures
Figure 1 Vaccine Sales Market Segmentation
Figure 2 Vaccine Sales Market by Type: Market Attractiveness Index
Figure 3 Vaccine Sales Market by Route of Administration: Market Attractiveness Index
Figure 4 Vaccine Sales Market by Age Group: Market Attractiveness Index
Figure 5 Vaccine Sales Market by Distribution Channel: Market Attractiveness Index
Figure 6 Vaccine Sales Market by Indication: Market Attractiveness Index
Figure 7 Vaccine Sales Market Attractiveness Index by Region
Figure 8 Vaccine Sales Market: Market Dynamics
Figure 9 Vaccine Sales Market: Impact Analysis
Figure 10 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 11 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 12 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 13 Short Term & Long Term Planning
Figure 14 Impact of U.S. and China Trade War
Figure 15 Most Impacted Countries
Figure 16 Vaccine Sales Market: Porter’s Five Forces Analysis
Figure 17 Vaccine Sales Market: PEST Analysis
Figure 18 Vaccine Sales Market Attractiveness Index by Type
Figure 19 Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 20 Vaccine Sales Market Share Forecast by Type, 2026, 2031, 2036 (%)
Figure 21 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 22 Subunit Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 23 Inactivated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 24 Inactivated Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 25 Live Attenuated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 26 Live Attenuated Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 27 mRNA Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 28 mRNA Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 29 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 30 Viral Vector Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 31 Vaccine Sales Market Attractiveness Index by Type
Figure 32 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 33 Vaccine Sales Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 34 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 35 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 36 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 37 Parenteral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 38 Nasal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 39 Nasal Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 40 Vaccine Sales Market Attractiveness Index by Age Group
Figure 41 Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 42 Vaccine Sales Market Share Forecast by Age Group, 2026, 2031, 2036 (%)
Figure 43 Adult Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 44 Adult Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 45 Paediatric Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 46 Paediatric Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 47 Vaccine Sales Market Attractiveness Index by Distribution Channel
Figure 48 Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 49 Vaccine Sales Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
Figure 50 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 51 Hospital & Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 52 Government Suppliers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 53 Government Suppliers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 54 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 55 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 56 Vaccine Sales Market Attractiveness Index by Indication
Figure 57 Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 58 Vaccine Sales Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 59 Viral Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 60 Viral Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 61 Bacterial Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 62 Bacterial Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 63 Cancer Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 64 Cancer Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 65 Allergy Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 66 Allergy Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 67 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 68 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 69 Vaccine Sales Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 70 Vaccine Sales Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 71 Vaccine Sales Market by Region, 2026-2036 (US$ Mn)
Figure 72 North America Vaccine Sales Market Attractiveness Index
Figure 73 North America Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 74 North America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 75 North America Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 76 North America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 77 North America Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 78 North America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 79 North America Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 80 North America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 81 North America Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 82 North America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 83 North America Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 84 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 85 North America Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 86 U.S. Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 87 Canada Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 88 Europe Vaccine Sales Market Attractiveness Index
Figure 89 Europe Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 90 Europe Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 91 Europe Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 92 Europe Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 93 Europe Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 94 Europe Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 95 Europe Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 96 Europe Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 97 Europe Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 98 Europe Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 99 Europe Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 100 Europe Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 101 Europe Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 102 Germany Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 103 UK Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 104 France Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 105 Italy Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 106 Spain Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 107 The Netherlands Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 108 Switzerland Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 109 Rest of Europe Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 110 Asia Pacific Vaccine Sales Market Attractiveness Index
Figure 111 Asia Pacific Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 112 Asia Pacific Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 113 Asia Pacific Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 114 Asia Pacific Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 115 Asia Pacific Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 116 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 117 Asia Pacific Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 118 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 119 Asia Pacific Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 120 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 121 Asia Pacific Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 122 Asia Pacific Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 123 Asia Pacific Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 124 Japan Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 125 China Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 126 India Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 127 Australia Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 128 South Korea Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 129 Singapore Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 130 Malaysia Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 131 Rest of Asia Pacific Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 132 Latin America Vaccine Sales Market Attractiveness Index
Figure 133 Latin America Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 134 Latin America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 135 Latin America Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 136 Latin America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 137 Latin America Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 138 Latin America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 139 Latin America Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 140 Latin America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 141 Latin America Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 142 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 143 Latin America Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 144 Latin America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 145 Latin America Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 146 Brazil Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 147 Mexico Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 148 Argentina Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 149 Chile Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 150 Rest of Latin America Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 151 MEA Vaccine Sales Market Attractiveness Index
Figure 152 MEA Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 153 MEA Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 154 MEA Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 155 MEA Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 156 MEA Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 157 MEA Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 158 MEA Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 159 MEA Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 160 MEA Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 161 MEA Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 162 MEA Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 163 MEA Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 164 MEA Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 165 GCC Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 166 South Africa Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 167 Rest of MEA Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 168 Bavarian Nordic: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 169 Bavarian Nordic: R&D, 2021-2025 (US$ Million, AGR %)
Figure 170 Bavarian Nordic: Regional Market Shares, 2025
Figure 171 CSL: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 172 CSL: R&D, 2021-2025 (US$ Million, AGR %)
Figure 173 CSL: Regional Market Shares, 2025
Figure 174 Emergent BioSolutions Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 175 Emergent BioSolutions Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 176 GSK plc: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 177 GSK plc: R&D, 2021-2025 (US$ Million, AGR %)
Figure 178 GSK plc: Regional Market Shares, 2025
Figure 179 Merck & Co., Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 180 Merck & Co., Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 181 Merck & Co., Inc.: Regional Market Shares, 2025
Figure 182 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 183 Moderna, Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 184 Pfizer Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 185 Pfizer Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 186 Sanofi: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 187 Sanofi: R&D, 2021-2025 (US$ Million, AGR %)
Figure 188 Sanofi: Regional Market Shares, 2025
Figure 189 AstraZeneca: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 190 AstraZeneca: R&D, 2021-2025 (US$ Million, AGR %)
Figure 191 AstraZeneca: Regional Market Shares, 2025
Figure 192 Takeda Pharmaceutical Company Limited: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 193 Takeda Pharmaceutical Company Limited: R&D, 2021-2025 (US$ Million, AGR %)
Figure 194 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2025
Figure 195 Valneva SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 196 Valneva SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 197 BioNTech SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 198 BioNTech SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 199 BioNTech SE: Business Segment Market Shares (%), 2025
ページTOPに戻る
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
